ArticleDiscover oncology2025
Cellular senescence related gene signature predicts prognosis and immune features in skin cutaneous melanoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- MicroRNAs and Cellular Senescence in Melanoma: An Underexplored Link to Tumor Progression-A Systematic Review with Bioinformatics Analyses.International journal of molecular sciences · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundSkin cutaneous melanoma (SKCM) is the deadliest skin cancer, with rising global incidence. Cellular senescence plays an essential role in tumorigenesis, progression, and immune modulation in cancer, however, its role in SKCM prognosis and immunotherapy response remains unclear.
methodsWe analyzed 279 senescence-related genes (SRGs) in 469 patients with SKCM from The Cancer Genome Atlas. A cellular senescence-related signature (CSRS) was constructed using univariate and LASSO Cox regression analyses. Kaplan-Meier survival curves and receiver operating characteristic (ROC) analyses were used to evaluate its predictive performance. Consensus clustering based on SRG expression stratified patients into distinct subgroups. External validation was performed using the GSE65904 dataset. We further assessed the association between CSRS, immune cell infiltration, and immunotherapy response. Additionally, immunohistochemistry validated the expression of prognosis-related SRGs and functional assays explored the role of RuvB-like AAA ATPase 2 (RUVBL2) in SKCM cells.
resultsThe CSRS effectively stratified patients with SKCM into high- and low-risk groups with significantly different survival outcomes and immune profiles. Moreover, our results suggest that higher levels of cellular senescence may enhance immunosurveillance and promote tumor suppression via a senescence-associated secretory phenotype-dependent mechanism. Based on the expression profiles of 113 SRGs, patients were classified into three distinct clusters, with Cluster 1 associated with the poorest prognosis. Among the identified SRGs, RUVBL2 was markedly upregulated in SKCM cells and its knockdown inhibited cell proliferation.
conclusionsThe CSRS is a robust prognostic and predictive biomarker in SKCM, highlighting the relevance of cellular senescence in shaping the tumor immune microenvironment and informing therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.